XML 32 R21.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Basis of Presentation and Summary of Significant Accounting Policies (Tables) | 9 Months Ended
--- | ---
Mar. 31, 2024
Notes Tables |
Schedule of restructuring charges | The restructuring and restructuring-related charges, including the impairment of assets held-for-sale, for periods presented were recorded in the Condensed Consolidated Statements of Earnings as follows (in thousands):
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Quarter Ended | ​ | Nine Months Ended
​ | ​ | March 31, | ​ | March 31,
​ | ​ | 2024 | ​ | 2024
Cost of sales | ​ | $ | 647 | ​ | $ | 1,821
Selling, general and administrative(1) | ​ | ​ | 903 | ​ | ​ | 11,153
Total | ​ | $ | 1,550 | ​ | $ | 12,974
​ | ​ | ​ | ​ | ​ | ​ | ​
(1) Restructuring actions impacting research and development are not material to separately disclose and have been included within Selling, general and administrative costs. ​ ​ Restructuring and restructuring-related costs by segment are as follows (in thousands):
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three months ended March 31, 2024
​ | ​ | ​ | Employee | ​ | ​ | Asset-related | ​ | ​ | Impairment of | ​ | ​ | ​
​ | ​ | ​ | severance | ​ | ​ | and other | ​ | ​ | assets held-for-sale | ​ | ​ | Total
Protein Sciences | ​ | $ | 28 | ​ | $ | 914 | ​ | $ | — | ​ | $ | 942
Diagnostics and Genomics | ​ | ​ | 265 | ​ | ​ | 90 | ​ | ​ | — | ​ | ​ | 355
Corporate | ​ | ​ | 117 | ​ | ​ | 136 | ​ | ​ | — | ​ | ​ | 253
Total | ​ | $ | 410 | ​ | $ | 1,140 | ​ | $ | — | ​ | $ | 1,550
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine months ended March 31, 2024
​ | ​ | ​ | Employee | ​ | ​ | Asset-related | ​ | ​ | Impairment of | ​ | ​ | ​
​ | ​ | ​ | severance | ​ | ​ | and other | ​ | ​ | assets held-for-sale | ​ | ​ | Total
Protein Sciences | ​ | $ | 2,978 | ​ | $ | 1,386 | ​ | $ | 6,038 | ​ | $ | 10,402
Diagnostics and Genomics | ​ | ​ | 1,004 | ​ | ​ | 90 | ​ | ​ | — | ​ | ​ | 1,094
Corporate | ​ | ​ | 1,310 | ​ | ​ | 168 | ​ | ​ | — | ​ | ​ | 1,478
Total | ​ | $ | 5,292 | ​ | $ | 1,644 | ​ | $ | 6,038 | ​ | $ | 12,974
​ The following table summarizes the changes in the Company’s accrued restructuring balance, which is included within Other current liabilities in the accompanying balance sheet. Other amounts reported as restructuring and restructuring-related costs in the accompanying statements of income have been summarized in the notes to the table (in thousands):
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | Employee | ​ | ​ | Asset-related | ​ | ​ | Impairment of | ​ | ​ | ​
​ | ​ | ​ | severance(1) | ​ | ​ | and other(2) | ​ | ​ | assets held-for-sale | ​ | ​ | Total
Expense incurred in the second quarter of 2024 | ​ | $ | 4,882 | ​ | $ | 504 | ​ | $ | 6,038 | ​ | $ | 11,424
Cash payments | ​ | ​ | (1,257) | ​ | ​ | (177) | ​ | ​ | — | ​ | ​ | (1,434)
Non-cash adjustments | ​ | ​ | — | ​ | ​ | (191) | ​ | ​ | (6,038) | ​ | ​ | (6,229)
Accrued restructuring actions balance as of December 31, 2023 | ​ | $ | 3,625 | ​ | $ | 136 | ​ | $ | — | ​ | $ | 3,761
Incremental expense incurred in the third quarter of 2024 | ​ | ​ | 133 | ​ | ​ | 1,140 | ​ | ​ | — | ​ | ​ | 1,273
Cash payments | ​ | ​ | (2,806) | ​ | ​ | (433) | ​ | ​ | — | ​ | ​ | (3,239)
Non-cash adjustments | ​ | ​ | — | ​ | ​ | (843) | ​ | ​ | — | ​ | ​ | (843)
Adjustments(3) | ​ | ​ | 277 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 277
Accrued restructuring actions balance as of March 31, 2024 | ​ | $ | 1,229 | ​ | $ | — | ​ | $ | — | ​ | $ | 1,229
(1) Relates to impacted employees’ final paycheck, separation payments, outplacement services, legal fees, and retention packages related to the closure or sale of certain distribution and manufacturing sites. (2) Primarily relates to impairment of right-of-use assets, lease termination fees, consulting fees, and expenses for changes to supporting IT systems that are enabling the Company to complete the restructuring initiatives. (3) Relates to the refinement of the accrual recorded in the second quarter of fiscal 2024. ​
Protein Sciences | QT Holdings Corporation |
Notes Tables |
Schedule of restructuring charges | The related restructuring charges for the year ended June 30, 2023 were recorded in the income statement as follows (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Employee | ​ | Asset | ​ | ​
​ |  | severance |  | impairment and other |  | Total
Selling, general and administrative | ​ | $ | 1,328 | ​ | $ | 842 | ​ | $ | 2,170
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Employee | ​ | Asset | ​ | ​
​ |  | severance |  | impairment and other |  | Total
Expense incurred in the first quarter of 2023 | ​ | $ | 1,328 | ​ | $ | 842 | ​ | $ | 2,170
Cash payments | ​ | ​ | (1,233) | ​ | ​ | (772) | ​ | ​ | (2,005)
Adjustments | ​ | ​ | (95) | ​ | ​ | (70) | ​ | ​ | (165)
Accrued restructuring actions balances as of June 30, 2023 | ​ | $ | — | ​ | $ | — | ​ | $ | —
Protein Sciences | Employee severance |
Notes Tables |
Schedule of restructuring charges | Restructuring actions, including cash and non-cash impacts, are as follows (in thousands):
​ | ​ | ​ | ​
​ | ​ | Employee
​ | ​ | severance
Expense incurred in fiscal year 2023 | ​ | $ | 1,677
Fiscal year 2023 cash payments | ​ | ​ | (762)
Fiscal year 2023 adjustments | ​ | ​ | (18)
Accrued restructuring actions balances as of June 30, 2023 | ​ | $ | 897
Fiscal year 2024 cash payments | ​ | ​ | (1,006)
Fiscal year 2024 adjustments(1) | ​ | ​ | 221
Accrued restructuring actions balances as of March 31, 2024(2) | ​ | $ | 112
(1) Fiscal year 2024 adjustments relate to the refinement of the accrual recorded in fiscal year 2023. (2) The remaining balance as of March 31, 2024 relates to employee severance that is paid out over a one-year period.

X
- Definition Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 5.P.3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 5.P.4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2 + Details
Name: | us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=tech_ProteinSciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=tech_QTHoldingsCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=us-gaap_EmployeeSeveranceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |